| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
IND Submission example | MURA-8518 Preclinical IL-18 therapeutic (oncology — intended for tumor-directed immune activation; no specific line of therapy disclosed) | IND | — | Subscribe to access the data. | Biologics | Oncology | |
IND Submission example | MURA-8518 Preclinical IL-18 therapeutic (oncology — intended for tumor-directed immune activation; no specific line of therapy disclosed) | IND | — | Subscribe to access the data. | Biologics | Oncology | |
IND Submission example | MURA-8518 Preclinical IL-18 therapeutic (oncology — intended for tumor-directed immune activation; no specific line of therapy disclosed) | IND | — | Subscribe to access the data. | Biologics | Oncology |
Recent Updates
Recently added Catalysts
Mural Oncology plc$2.04
+0.01 (+0.49%)
C 40Pipeline Score Fair Value Biotech · Clinical
Market Cap
35.21 M
EPS
-6.93
P/E Ratio
-
Value Trade
259.92 K
0 %
Week
-2.4 %
1 Month
-1.93 %
3 Month
-22.52 %
6 Month
-87.84 %
5 Year
-87.84 %
All Time
Cash Data
Cash Position
12.35 K
Monthly Burn
12.35 K
Runway
12,345 mo
Overview
Volume
127.78 K
52 Week Range
0.95 - 4.74
% held by Insiders
25.71 %
% held by Institutions
54.49 %
Enterprise Value
-21.83 M
Total Shares
17.33 M
Short %
2.77 %
Float Shares
15.62 M
Company Description
locked
Upcoming Catalyst
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
2024-11-08 | Nemvaleukin alfa | Phase 1/2 data readout | Phase 1/2 | — | – | – | – |
2024-11-08 | Nemvaleukin alfa | Phase 1/2 data readout | Phase 1/2 | — | – | – | – |
2024-11-08 | Nemvaleukin alfa | Phase 1/2 data readout | Phase 1/2 | — | – | – | – |
Drug Pipeline Intelligence
C40
Pipeline Score $60M
Pipeline ValueFair Value
Valuation Signal2
Drugs Scored1.7x
rNPV / MCap Top 56%
Micro Cap (rank 402 of 912)
Percentile RankMural Oncology plc carries a moderate pipeline score (40/100), with $2.9B risk-adjusted pipeline value, led by Nemvaleukin alfa in Advanced Solid Tumor (Phase 1).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nemvaleukin Alfa Small molecule | Squamous Cell Carcinoma of Head and Neck | Phase 2 | NCT04144517 | 10% | $2.9B | COMPLETED | 14 | - | - | Jan 7, 2022 | - | Oct 16, 2024 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
nemvaleukin | platinum-resistant ovarian cancer | Phase 3 | 2025-03-25 | median overall survival nemvaleukin: 10.1 months; median overall survival chemotherapy: 9.8 months; hazard ratio: 0.98 Read More | Mural Oncology Provides Update on Phase 3 ARTISTRY-7 Trial of Nemvaleukin in Combination with KEYTRUDA® (pembrolizumab) in Patients with Platinum-Resistant Ovarian Cancer Read More | |
nemvaleukin | platinum-resistant ovarian cancer | Phase 3 | 2025-03-25 | median overall survival nemvaleukin: 10.1 months; median overall survival chemotherapy: 9.8 months; hazard ratio: 0.98 Read More | Mural Oncology Provides Update on Phase 3 ARTISTRY-7 Trial of Nemvaleukin in Combination with KEYTRUDA® (pembrolizumab) in Patients with Platinum-Resistant Ovarian Cancer Read More | |
nemvaleukin | platinum-resistant ovarian cancer | Phase 3 | 2025-03-25 | median overall survival nemvaleukin: 10.1 months; median overall survival chemotherapy: 9.8 months; hazard ratio: 0.98 Read More | Mural Oncology Provides Update on Phase 3 ARTISTRY-7 Trial of Nemvaleukin in Combination with KEYTRUDA® (pembrolizumab) in Patients with Platinum-Resistant Ovarian Cancer Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in MURA
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
MURA Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
Competitive Position
How MURA ranks across every disease it competes inCompetitive Position is a premium feature
See how MURA ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial